CANCER BIOMARKERS
DE602018084933T2Active Publication Date: 2025-08-27ELYPTA AB
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- DE602018084933
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-03-07
- Filing Date
- 2018-03-07
- Publication Date
- 2025-08-27
- Estimated Expiration
- 2038-03-07
AI Technical Summary
Technical Problem
Current cancer diagnostics rely heavily on biomarkers like PSA and CEA, which have low sensitivity and specificity, necessitating the development of more accurate and non-invasive methods for early detection and monitoring.
Method used
Utilizing glycosaminoglycans (GAGs) such as chondroitin sulfate (CS), heparan sulfate (HS), and hyaluronic acid (HA) in body fluids for their differential levels and chemical compositions as biomarkers to detect cancer, employing methods like electrophoresis and mass spectrometry for analysis.
Benefits of technology
Provides highly specific and sensitive assays for cancer detection in accessible body fluids, enabling early diagnosis, prognosis, and monitoring of cancer progression and treatment response.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.